Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 427 entries
View as:

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00413036 Org: User:
Start: 06/30/06 End: 05/31/11 Due: 05/31/12

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Phase: N/A Priority: Normal
NCT ID: NCT04140305 Org: User:
Start: 01/16/20 End: 05/15/25 Due: 05/15/26

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02848001 Org: User:
Start: 11/14/16 End: 04/11/24 Due: 04/11/25

Longterm Follow-up of Subjects Treated With bb2121

Phase: N/A Priority: Normal
NCT ID: NCT02786511 Org: User:
Start: 04/28/16 End: 10/11/19 Due: 10/11/20

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Phase: N/A Priority: Normal
NCT ID: NCT02085798 Org: User:
Start: 12/17/12 End: 12/14/18 Due: 12/14/19

A Research Study for Patients With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00106613 Org: User:
Start: 05/01/03 End: 08/01/04 Due: 08/01/05

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03958864 Org: User:
Start: 04/04/19 End: 06/13/19 Due: 06/13/20

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02273739 Org: User:
Start: 12/08/14 End: 06/03/16 Due: 06/03/17

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase: N/A Priority: Normal
NCT ID: NCT02494258 Org: User:
Start: 10/22/15 End: 04/14/25 Due: 04/14/26

A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02670746 Org: User:
Start: 10/01/15 End: 11/28/17 Due: 11/28/18

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02400242 Org: User:
Start: 05/07/15 End: 06/03/24 Due: 06/03/25

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Phase: N/A Priority: Normal
NCT ID: NCT03106324 Org: User:
Start: 03/31/17 End: 01/13/26 Due: 01/13/27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01962103 Org: User:
Start: 12/04/13 End: 11/06/18 Due: 11/06/19

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Phase: N/A Priority: Normal
NCT ID: NCT00065156 Org: User:
Start: 06/01/03 End: 08/01/08 Due: 08/01/09

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06356129 Org: User:
Start: 06/19/24 End: 11/20/29 Due: 11/20/30

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT04753697 Org: User:
Start: 02/22/21 End: 08/29/24 Due: 08/29/25

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT02902900 Org: User:
Start: 04/01/15 End: 05/31/22 Due: 05/31/23

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02577406 Org: User:
Start: 12/30/15 End: 03/25/24 Due: 03/25/25

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01169298 Org: User:
Start: 07/01/10 End: 12/20/13 Due: 12/20/14

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01915498 Org: User:
Start: 08/27/13 End: 10/31/23 Due: 10/31/24

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03850067 Org: User:
Start: 03/12/19 End: 07/16/24 Due: 07/16/25

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPĪ±, in Participants With Advanced Solid and Hematologic Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03783403 Org: User:
Start: 03/01/19 End: 08/05/24 Due: 08/05/25

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase: N/A Priority: Normal
NCT ID: NCT03930953 Org: User:
Start: 05/20/19 End: 04/18/27 Due: 04/18/28

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00622336 Org: User:
Start: 04/01/03 End: 11/25/13 Due: 11/25/14

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06163898 Org: User:
Start: 02/27/24 End: 05/30/25 Due: 05/30/26